Zacks Investment Research downgraded shares of DBV Technologies (NASDAQ:DBVT) from a hold rating to a sell rating in a report released on Monday.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

Other research analysts also recently issued reports about the company. Deutsche Bank increased their price objective on DBV Technologies from $46.00 to $56.00 in a research note on Sunday, October 8th. Morgan Stanley downgraded DBV Technologies from an overweight rating to an equal weight rating in a research note on Monday, October 23rd. Leerink Swann set a $49.00 price objective on DBV Technologies and gave the company an outperform rating in a research note on Monday, October 23rd. Societe Generale downgraded DBV Technologies from a buy rating to a sell rating in a research note on Tuesday, October 24th. Finally, Barclays cut their target price on DBV Technologies from $58.00 to $30.00 and set an overweight rating for the company in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $49.63.

DBV Technologies (NASDAQ:DBVT) opened at $24.01 on Monday. DBV Technologies has a 52 week low of $20.58 and a 52 week high of $50.57.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC purchased a new position in shares of DBV Technologies during the 3rd quarter worth $132,000. Quantbot Technologies LP purchased a new position in shares of DBV Technologies during the 3rd quarter worth $146,000. Alps Advisors Inc. grew its holdings in shares of DBV Technologies by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 47,477 shares of the company’s stock worth $2,015,000 after purchasing an additional 3,964 shares during the period. Dynamic Technology Lab Private Ltd grew its holdings in shares of DBV Technologies by 87.6% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 11,655 shares of the company’s stock worth $495,000 after purchasing an additional 5,441 shares during the period. Finally, Commonwealth Equity Services Inc purchased a new position in shares of DBV Technologies during the 3rd quarter worth $233,000. Institutional investors and hedge funds own 46.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/12/28/zacks-investment-research-lowers-dbv-technologies-dbvt-to-sell.html.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get a free copy of the Zacks research report on DBV Technologies (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.